How to Formulate a Barrier Repair Moisturiser: Full Formula & Protocol | Onerchem
◆ Formulation Guide
How to Formulate a Barrier Repair Moisturiser: Complete Formula & Processing Protocol
A practical formulation guide for a ceramide-based barrier repair moisturiser — covering emulsion architecture, ceramide solubilisation, active selection rationale, step-by-step processing protocol, and stability testing requirements. Suitable for sensitive, compromised, and atopic-prone skin positioning.
Formula design principles — what a barrier repair formula must achieve
A barrier repair moisturiser has a more specific functional brief than a general hydrating cream. The target is not simply to add moisture — it is to restore the structural integrity of the stratum corneum lipid matrix, reduce transepidermal water loss (TEWL), and support the skin's natural recovery from compromise.
This requires three design decisions that differ from standard moisturiser formulation:
- Lamellar emulsion architecture — A standard O/W emulsion disperses oil droplets in water. A barrier repair emulsion should ideally form lamellar liquid crystal structures — ordered bilayer arrangements of emulsifier and lipid that mimic the natural stratum corneum lamellar structure. Cetearyl Alcohol-based self-emulsifying systems are the most practical route to lamellar architecture in commercial production. This structural consideration determines emulsifier selection before any other formulation decision.
- pH 5.0–5.5 — Physiological skin surface pH is approximately 4.5–5.5. Barrier-compromised skin benefits most from topical products that match or support this pH range. Serine proteases involved in natural desquamation and barrier maintenance function optimally at pH 5.0–5.5. Formulas at pH above 6.5 may interfere with these processes over repeated use.
- Fragrance-free, low-irritant preservative system — The target consumer for a barrier repair formula typically has sensitive or compromised skin. Fragrance is the leading cause of cosmetic contact sensitisation and must be excluded. Phenoxyethanol + Ethylhexylglycerin is the standard choice — the mildest broadly effective preservative system available.
The critical solubilisation challenge in this formula is Ceramide NP. Get the ceramide processing step right and everything else is straightforward. Get it wrong and you will have visible crystalline particles in the finished product within weeks.
Active ingredient selection — five mechanisms, one barrier
Ceramide NP
Stratum corneum lipid — structural
Mechanism
Replaces depleted stratum corneum ceramides — restores lamellar lipid bilayer integrity and reduces TEWL
Formula %
0.5% (as pure ceramide in oil phase)
Phase
Oil phase — requires heat solubilisation
Squalane
Barrier lipid — structural & occlusive
Mechanism
Mimics endogenous squalene — acts as barrier lipid and Ceramide NP co-solvent during processing
Formula %
5.0%
Phase
Oil phase
Sodium Hyaluronate
Humectant — hydration reservoir
Mechanism
Binds water in epidermis — high MW surface film, low MW penetrating reservoir
Formula %
0.10% HMW + 0.05% LMW
Phase
Water phase — cold dispersion
D-Panthenol
Wound healing — barrier recovery
Mechanism
Converts to Pantothenic Acid in skin — accelerates wound healing, keratinocyte proliferation, barrier restoration
Formula %
1.0%
Phase
Water phase or cool-down
Ectoine
Extremolyte — anti-inflammatory
Mechanism
Stabilises membrane structures, reduces inflammatory cytokine release (IL-1β, TNF-α) — clinical data in atopic dermatitis
Formula %
1.0%
Phase
Water phase or cool-down
Alpha-Bisabolol
Soothing — anti-irritant
Mechanism
Inhibits inflammatory mediators, reduces erythema — ideal for reactive and sensitised skin positioning
Formula %
0.3%
Phase
Oil phase
Complete formula — Ceramide Barrier Repair Moisturiser
| Ingredient (INCI) | % | Function / Notes |
|---|---|---|
| Phase A — Water Phase (ambient, then heat to 70–75°C) | ||
| Aqua (Water) | q.s. to 100 | Base — demineralised, conductivity <5 µS/cm |
| Glycerin | 5.00% | Primary humectant, co-solvent, processing aid |
| Sodium Hyaluronate (HMW, 1500–1800 kDa) | 0.10% | Surface hydration film — disperse cold first |
| Sodium Hyaluronate (LMW, 10–50 kDa) | 0.05% | Penetrating hydration — disperse cold first |
| Disodium EDTA | 0.05% | Metal chelation — improves emulsion stability and preservative efficacy |
| Panthenol (D-Panthenol) | 1.00% | Barrier repair, wound healing — add to water phase |
| Phase B — Oil Phase (heat to 70–75°C, melt together) | ||
| Cetearyl Alcohol | 3.00% | Emulsifier / consistency agent — supports lamellar architecture |
| Glyceryl Stearate SE | 2.50% | Primary O/W emulsifier — gentle, non-ionic |
| Ceteareth-20 | 1.00% | Co-emulsifier — HLB booster for stable emulsion |
| Squalane | 5.00% | Barrier lipid + Ceramide NP co-solvent — add Ceramide NP to warm Squalane first |
| Ceramide NP (≥98% purity) | 0.50% | Pre-dissolve in warm Squalane at 70°C before adding to Phase B — see processing note |
| Caprylic/Capric Triglyceride | 3.00% | Lightweight emollient, aids Ceramide NP solubilisation |
| Alpha-Bisabolol (natural) | 0.30% | Soothing, anti-irritant — oil-soluble, add to oil phase |
| Tocopherol (Vitamin E) | 0.20% | Antioxidant — protects oil phase from oxidation during processing and on shelf |
| Phase C — Cool-down Actives (below 40°C) | ||
| Ectoine (CAS 96702-03-3, ≥99%) | 1.00% | Anti-inflammatory, membrane stabilisation — heat-stable but add cool for best practice |
| Niacinamide | 2.00% | Barrier support, ceramide synthesis stimulation, anti-inflammatory |
| Phase D — Preservation & pH (below 35°C) | ||
| Phenoxyethanol | 0.90% | Primary preservative — mild, globally accepted |
| Ethylhexylglycerin | 0.10% | Preservation booster, skin conditioning |
| Lactic Acid (10% solution) — to pH 5.0–5.5 | q.s. | pH adjustment — physiological range for barrier repair |
| TOTAL | 100% | Target pH 5.0–5.5 · Target viscosity 15,000–30,000 cP · Appearance: white cream |
Onerchem Ingredients in This Formula
Ceramide NP ·
Squalane ·
Sodium Hyaluronate ·
D-Panthenol ·
Ectoine ·
Alpha-BisabololSamples available for all actives. Request samples →
Processing protocol — step by step
1
Pre-dissolve Ceramide NP in warm Squalane
This is the most critical step. Combine Ceramide NP (0.5%) with Squalane (5.0%) in a separate vessel. Heat to 70–75°C under gentle stirring until Ceramide NP is fully melted and dissolved — the mixture should be clear to very slightly hazy. Do not proceed until complete dissolution is confirmed. Undissolved Ceramide NP will re-crystallise in the finished emulsion, producing visible white particles.
🌡 70–75°C · Stir until clear
2
Prepare Phase A — water phase
Disperse Sodium Hyaluronate (both grades separately) in cold demineralised water first — allow 20 minutes hydration. Add Glycerin, Disodium EDTA, and Panthenol. Mix until homogeneous. Heat water phase to 70–75°C.
🌡 Cold dispersion → heat to 70–75°C
3
Prepare Phase B — oil phase
Melt Cetearyl Alcohol, Glyceryl Stearate SE, and Ceteareth-20 together at 70–75°C. Add Caprylic/Capric Triglyceride, Tocopherol, and Alpha-Bisabolol. Finally add the pre-dissolved Ceramide NP/Squalane mixture (from Step 1, kept warm at 70°C). Mix Phase B until fully homogeneous.
🌡 70–75°C throughout
4
Emulsification — add Phase B to Phase A
Add Phase B slowly to Phase A under high-shear mixing (homogeniser or high-speed mixer) while both phases are at 70–75°C. Add B to A — not A to B. Mix at high shear for 5–10 minutes until a uniform cream forms. Begin cooling immediately after emulsification is complete — do not hold at elevated temperature.
🌡 Both phases at 70–75°C · High shear
5
Cool to 40°C — add Phase C actives
Cool under gentle agitation to below 40°C. Add Ectoine and Niacinamide. Mix gently until fully incorporated. Both are water-soluble and incorporate readily into the aqueous phase of the emulsion. Continue cooling to below 35°C.
🌡 Below 40°C
6
Add Phase D — preservatives and pH adjustment
Below 35°C, add Phenoxyethanol and Ethylhexylglycerin. Mix until homogeneous. Measure pH and adjust to 5.0–5.5 with Lactic Acid (10% working solution). Mix thoroughly after each addition — pH in cream emulsions equilibrates more slowly than in aqueous gels. Allow 5 minutes mixing before re-checking pH.
🌡 Below 35°C · Target pH 5.0–5.5
7
QC and fill
Measure: pH (5.0–5.5 ✓), viscosity (15,000–30,000 cP at 25°C ✓), appearance (uniform white cream, no visible particles ✓). Inspect under magnification for Ceramide NP crystallisation — any visible white specks indicate incomplete dissolution in Step 1. Fill stability samples and submit for microbial challenge (PET) testing.
Ceramide NP solubilisation — the detail that determines success or failure
Ceramide NP has a melting point of approximately 87–92°C as a pure compound. In formulation, it is solubilised at lower temperatures by using a carrier oil system — but the solubilisation must be complete before emulsification, and the emulsion must be processed in a way that keeps the ceramide in solution.
Why crystallisation occurs and how to prevent it
- Complete dissolution at high temperature first — Ceramide NP must be fully dissolved in the oil phase before emulsification. The Squalane + Caprylic/Capric Triglyceride combination in this formula provides sufficient solubilisation capacity for 0.5% Ceramide NP. If you increase Ceramide NP above 1%, increase the oil phase proportion proportionally or use a pre-solubilised commercial Ceramide NP dispersion.
- Rapid cooling after emulsification — Slow cooling gives Ceramide NP time to re-crystallise from the dispersed oil droplets before the emulsion stabilises. Cool rapidly to below 40°C after emulsification is complete. Do not hold the batch at intermediate temperatures (50–60°C) for extended periods.
- Cetearyl Alcohol supports lamellar trapping — Cetearyl Alcohol forms lamellar liquid crystal structures at the oil-water interface that can physically trap Ceramide NP within the lamellar bilayers, reducing recrystallisation tendency. This is why Cetearyl Alcohol-based emulsifier systems are preferred for ceramide formulas over simpler non-ionic systems.
- Storage temperature sensitivity — Finished Ceramide NP emulsions can develop crystallisation during freeze-thaw cycles or if stored below 10°C. Include freeze-thaw cycling (5 cycles, -10°C to +25°C) in your stability protocol and assess under magnification at each cycle.
- Do not add Ceramide NP directly to the combined emulsion — Adding undissolved Ceramide NP to the water phase, or to the finished emulsion, will always produce a defective product. Pre-dissolution in the oil phase at 70–75°C before emulsification is non-negotiable.
Product Page · Barrier Repair
Ceramide NP — HPLC ≥98%, batch COA, solubilisation guidance included
View Product
→
Stability testing requirements
Barrier repair moisturisers require additional stability parameters beyond standard cream testing, specifically for Ceramide NP crystallisation and emulsion lamellar structure integrity.
- Accelerated stability (40°C/75% RH, 3 months) — Monitor pH (±0.3 from target), viscosity (±20%), appearance (no phase separation, no crystalline particles under 10x magnification), colour. Run in proposed final packaging — cream textures are more packaging-dependent than gels.
- Freeze-thaw cycling (5 cycles, -10°C/+25°C) — Critical for ceramide-containing formulas. Assess appearance under 10x magnification after each cycle. Any visible white crystalline particles indicate formulation instability requiring correction before launch.
- Refrigerated storage (4°C, 3 months) — Check for phase separation, texture change, or Ceramide NP crystallisation. Some thickening at 4°C is acceptable if the product returns to normal consistency at room temperature.
- Microbial challenge (PET, ISO 11930) — Required for all leave-on emulsions. Target Category A or B compliance. The Phenoxyethanol + Ethylhexylglycerin system should achieve Category A in most formulations at this pH range.
- TEWL measurement (optional but recommended) — For premium barrier repair positioning, in-vitro or in-vivo TEWL measurement demonstrates functional efficacy beyond stability compliance. A 15–25% TEWL reduction versus untreated control is a commercially meaningful claim threshold.
Frequently asked questions
Pre-dissolve Ceramide NP in warm Squalane (or Caprylic/Capric Triglyceride) at 70–75°C until fully clear before adding to the main oil phase. Ceramide NP requires at least 10 parts oil carrier per 1 part ceramide for complete dissolution. Never add undissolved Ceramide NP directly to an emulsion — it will re-crystallise and produce visible particles in the finished product.
Ceramide NP (formerly Ceramide 3) is the primary stratum corneum ceramide and the most clinically studied — suitable as the sole ceramide in a barrier repair formula. Ceramide AP features an alpha-hydroxy fatty acid chain and contributes to lamellar organisation. Ceramide EOP is the esterified omega-hydroxy form that links to the cornified envelope. A ceramide complex (NP:AP:EOP approximately 3:1:1) more closely mimics natural stratum corneum composition and is used in premium barrier repair formulations.
Cetearyl Alcohol + Glyceryl Stearate + Ceteareth-20 is the preferred system for ceramide moisturisers. Cetearyl Alcohol forms lamellar liquid crystal structures at the oil-water interface that can trap ceramide NP within the bilayers, reducing recrystallisation tendency and supporting the formula's barrier repair mechanism. Avoid ionic emulsifiers — they disrupt lamellar structure.
pH 5.0–5.5 — matching physiological skin surface pH and supporting optimal serine protease activity for natural desquamation and barrier maintenance. Above pH 6.5, these processes may be disrupted over repeated use. For compromised or sensitised skin, pH 5.0–5.5 provides barrier support without the mild irritation risk of very low pH formulas.
Published clinical data supports significant barrier support and anti-inflammatory activity at 0.5–2.0% Ectoine. At 0.5%, measurable TEWL improvement is documented. At 1.0–2.0%, significant reduction in inflammatory markers in atopic dermatitis models is shown. The formula in this guide uses 1.0% — an evidence-supported concentration providing meaningful clinical activity at reasonable cost-in-use.